OA18.03 Surfaceome of TP53-Mutant NSCLC Reveals a Distinct Subtype with Immunotherapy Vulnerability, Characterized by Co-occurring PTPRD Mutant

TP53-mutant non-small cell lung cancer (NSCLC) is considered high heterogeneity without effective targeted therapy. Despite immunotherapy in NSCLC has undergone remarkable advances, whether TP53-mutant NSCLC patients can benefit from immunotherapy and the target population is molecularly specific remain to be elucidated.